New draft USPSTF guidance on screening for risk of prostate cancer (the details)

As indicated earlier this morning, the US Preventive Services Task Force (USPSTF) has issued new draft guidance on screening for risk of prostate cancer. Access to all the relevant details is provided below: … READ MORE …

USPSTF changes guidance on testing for risk of prostate cancer

As yet we have not seen the details, but, according to a report on National Public Radio early this morning, the US Preventive Services Task Force (USPSTF) has stated that men up to age 70 should discuss the risk and benefits of PSA testing with their doctors and then make individual decisions about whether to get tested. … READ MORE …

MRI as a means of screening for prostate cancer? Probably not!

A report on the HealthDay web site related to a presentation about the role of MRI scanning in the diagnosis of localized prostate cancer seems to demonstrate a significant division of views about the value of standardized use of mpMRI in the diagnosis of prostate cancer. … READ MORE …

Family history, PSA testing, and risk for diagnosis with prostate cancer

A presentation at the ongoing annual meeting of the European Association of Urology (EAU), in London, England, has reported (perhaps unsurprisingly) that PSA testing for risk of prostate cancer based on family history alone is not a very good idea. … READ MORE …

And now … data from the PCLO trial at 15 years …

A new update on the prostate cancer outcomes of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial has given us a rather different interpretation of the meaning of the data from this trial — although whether that “meaning” actually has “meaning” is probably up for debate. … READ MORE …

Responsibilities unasked for and the role of the USPSTF

A commentary in this week’s issue of the New England Journal of Medicine provides some valuable, historical insight into how it was that the U.S. Preventive Services Task Force (USPSTF) ended up with responsibilities that many of its members never wanted. … READ MORE …

Suggestions of bias in decisions about who got biopsies in the SELECT trial

A re-analysis of data from men participating in the placebo arms of the Prostate Cancer Prevention Trial (PCPT) and the Selenium and Vitamin E Cancer Prevention Trial (SELECT) has suggested a problem with bias in decisions about who gets biopsies during certain types of clinical trial. … READ MORE …